PEDIATRICS Vol. 71 No. 1 January 1983, pp. 139
This Article
Right arrow Full Text (PDF)
Right arrow P3Rs: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when P3Rs are posted
Right arrow Alert me if a correction is posted
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My File Cabinet
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via CrossRef
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by WRIGHT, J. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by WRIGHT, J. M.

Carbamazepine-Isoniazid Interaction

J. M. WRIGHT MD, PHD, FRCP(C)1

1 Departments of Pharmacology and Medicine, The University of British Columbia, 2176 Health Sciences Mall, Vancouver, British Columbia, Canada V6T 1W5

To the Editor.—

The case report of carbamazepine intoxication secondary to isoniazid administration recently described in this journal1 is a clinically significant interaction.

I have previously presented2 a similar case in which a patient receiving carbamazepine, valproate, and nitrazepam developed severe carbamazepine intoxication when isoniazid was added to the drug regimen. The patient was determined to have inherited the slow acetylator phenotype. On careful rechallenge, 300 mg of isoniazid increased carbamazepine steady-state serum concentrations by 85% and decreased carbamazepine clearance by 45%.




This article has been cited by other articles:


Home page
 Antimicrob. Agents Chemother.Home page
Z. Desta, N. V. Soukhova, and D. A. Flockhart
Inhibition of Cytochrome P450 (CYP450) Isoforms by Isoniazid: Potent Inhibition of CYP2C19 and CYP3A
Antimicrob. Agents Chemother., February 1, 2001; 45(2): 382 - 392.
[Abstract] [Full Text]